Regeneron Advances in Cancer Treatment with SNS-101 Study Update

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals, in collaboration with Sensei Biotherapeutics, is conducting a Phase 1/2 study titled A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors. The study aims to assess the safety and efficacy of SNS-101, a novel anti-VISTA IgG1 monoclonal antibody, both as a standalone treatment and in combination with cemiplimab for patients with advanced solid tumors.

The study tests two interventions: SNS-101, an anti-VISTA monoclonal antibody, and cemiplimab, an existing immunotherapy drug. SNS-101 is administered intravenously every 21 days, either alone or in combination with cemiplimab, to evaluate its potential in treating solid tumors.

This open-label, non-randomized study follows a sequential intervention model with no masking. It is primarily focused on treatment, involving three parts: monotherapy dose escalation, combination dose escalation, and cohort expansion.

The study began on May 31, 2023, and is currently active but not recruiting. The last update was submitted on August 14, 2025. These dates are crucial as they mark the study’s progression and timeline for potential results.

The study’s progress could influence Regeneron’s stock performance, as positive outcomes may enhance investor confidence and market position, especially in the competitive oncology sector. The collaboration with Sensei Biotherapeutics also highlights strategic partnerships in advancing cancer treatment options.

The study is ongoing, with further details available on the ClinicalTrials portal.